Reported 2 months ago
On a recent episode of CNBC's 'Mad Money', Jim Cramer praised Oneok (NYSE: OKE) as a solid investment after its strong quarterly earnings report, while recommending investors stay away from Dexcom (NASDAQ: DXCM) due to disappointing results and unclear explanations for its performance. He also expressed confidence in KeyCorp and CRISPR Therapeutics as promising investment options.
Source: YAHOO